University of Miami Health System

Although immune checkpoint inhibitors can yield dramatic results and give some patients many years of life, some patients do not yield benefit.

Patients with chronic lymphocytic leukemia and related blood cancers are often prescribed targeted drugs called BTK inhibitors.

The blood cancer expert comes to Sylvester Comprehensive Cancer Center after leading the discovery and testing of several immunotherapy approaches.

Shanta Dhar, PhD, assistant director of Technology and Innovation at Sylvester Comprehensive Cancer Center, has been named a fellow of the National Academy of Inventors.

Macarena de la Fuente, MD, becomes the first Hispanic elected and will represent neurology on the multidisciplinary board.

Dolphins Challenge Cancer and AutoNation are teaming up to address the links between social, economic and environmental factors and breast cancer mortality.

BioFlorida, a statewide association for Florida’s life sciences industry, has named Stephen D. Nimer, MD, director of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, “Researcher of the Year.”

A large research project found that whole genome sequencing can provide much more information about classic Hodgkin lymphoma than exome sequencing, which reads only protein-coding genes.

Top epigenetics researchers from around the world gathered in South Beach for the Fifth Biennial Miami Epigenetics and Cancer Symposium, hosted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

More than 160 attendees took part in a day of learning and collaboration as Sylvester Comprehensive Cancer Center hosted the inaugural Cancer Survivorship Symposium.

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that a protein complex that governs gene expression sometimes gets rewired during breast cancer to help estrogen receptor positive tumors resist endocrine therapies and become more aggressive.

Antonio Iavarone, MD, has made a decades-long commitment to finding better treatments for glioblastoma and other aggressive brain tumors. As the new deputy director of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, he will have opportunities to do even more.

The Florida Department of Health has awarded Nagaraj Nagathihalli, PhD, an associate professor at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, a $583,200 grant to study tobacco risk, tumor progression, and therapeutic options for pancreatic cancer.

Sophia George, PhD, is hoping to find new strategies for early detection of ovarian cancer, a disease that is particularly deadly for African American, Caribbean, and Jewish women.

Sylvester Comprehensive Cancer Center researchers Lluis Morey, PhD, and Ramiro Verdun, PhD, have received a $1.8 million NIH R01 grant to study the epigenetic mechanisms that drive head and neck cancers.

Scott M. Welford, Ph.D., is the new Tumor Biology Research Program co-leader at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

What began as a small community effort seven decades ago has resulted in a new series of grants to accelerate groundbreaking research at Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine.

Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities.

New research illuminates the mechanisms that make B-cell lymphomas resistant to important immunotherapy

Innovative advances in personalized care, immunotherapy, and targeted treatment for people with many types of cancer were the focus of the inaugural Miami Precision Medicine Conference, held April 2 at the Ritz-Carlton in Fort Lauderdale.